News

The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with Kalydeco (ivacaftor) as a treatment for cystic fibrosis (CF) in people 12 and older who have either two F508del mutations or one F508del mutation and…

Nontuberculous mycobacteria (NTM), a type of infectious bacteria, is able to survive being dried for a full day, a study found, suggesting that drying is not a sufficient way to disinfect nebulizers used by people with cystic fibrosis (CF). The study, “Susceptibility of the Mycobacterium…

AR-501, an inhaled treatment candidate for chronic lung infections in people with cystic fibrosis (CF), has been deemed safe and well-tolerated in healthy volunteers, results from the first part of a Phase 1/2a clinical trial show. The trial’s safety monitoring committee (SMC) and a data safety monitoring board…

Renovion has raised $8.1 million in a financing round, supporting further development and planned clinical testing of ARINA-1, a nebulized treatment for chronic lung diseases like cystic fibrosis (CF) and non-CF bronchiectasis, and for lung transplants. “Patient and laboratory studies have…

Exposure to second-hand smoke in infants and children with cystic fibrosis (CF) is linked to changes in levels of metabolites and activation of signaling pathways that enhance inflammation, a study has found. The findings suggest exposure to second-hand smoke is a potentially important environmental factor in CF. The study…

The third annual CF FamilyCon, a free and online event that connects people with cystic fibrosis (CF) and their extended families and friends with one another — and to others — takes place this weekend. This two-day event, supported by the Cystic Fibrosis Foundation, is set for…